Biontech starts the new year with a strong increase in profits
Created: 05/09/2022, 12:05 p.m
The Biontech logo is on flags in front of the headquarters.
© Sebastian Gollnow/dpa/archive image
The corona vaccine manufacturer Biontech was again able to significantly increase sales and profits in the first quarter.
In the quarter that ended at the end of March, there was a net profit of around 3.70 billion euros in the books after around 1.13 billion euros in the same period last year, as the company announced on Monday in Mainz.
Sales increased from 2.05 billion euros to 6.37 billion euros.
Mainz - When presenting the new figures, Biontech confirmed its sales forecast for its corona vaccine of 13 billion to 17 billion euros for the current financial year.
According to their own statements, Biontech and its US partner Pfizer are still examining possible successor versions of the previous Covid 19 vaccine.
Among other things, this involves a vaccine candidate based on the omicron variant and so-called bivalent vaccines that are directed against omicron and other Sars-CoV-2 strains.
An update of the data from the clinical trials that started in January is "expected in the coming weeks and made available to the regulatory authorities," the company said.
more on the subject
Mastercard: Jump in profits at the beginning of the year
Twitter with significant user growth
Kion exceeds dampened expectations: no prognosis
In the past fiscal year, Biontech had generated a net profit of around 10.3 billion euros.
Sales were almost 19 billion euros.
dpa
